web analytics
8.5 C
Munich
Wednesday, December 1, 2021

Regen BioPharma Inc (OTCMKTS: RGBP) Heats Up as Biotech Up Lists & Signs LOI to Acquire Canary Oncoceutics, Inc

Regen BioPharma Inc (OTCMKTS: RGBP) is getting noticed by some heavy hitters after the Company reported earlier this week in its first press release since going “pink current” it has signed a non-binding LOI to acquire Canary Oncoceutics, Inc., a new company developing in vitro precision oncology tests using cellular technology. This comes after RGBP skyrocketed to $0.175 earlier this year when its subsidiary KCL Therapeutics, Inc. entered into the initial agreement with Oncology Pharma, Inc. whereby KCL granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021. In order for this acquisition to close, Regen must raise $50 million to support the development of the diagnostic platform. 

Canary Oncoceutics, Inc. is developing a precision oncology testing platform that will complement existing cancer genomic testing. Cancer genomic testing involves analyzing a sample of a cancer tumor to see how active certain genes are and if they are abnormally modified. By identifying the genetic alterations that are unique to a patient’s individual cancer, doctors are able to identify specific drugs designed to target those mutations. However, the list of drugs generated by genomic testing may be quite extensive and different patients respond differently to the same drug. Canary is developing tests that take those recommendations and test them on a patient’s tumor in a laboratory setting thereby allowing doctors to refine the list of recommendations generated through genomic testing down to those drugs or drug combinations which will work best on that specific patient. According to CEO David Koos The global cancer diagnostics market was $168 billion in 2020 and is expected to reach $280 billion by 20281.”  

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders.  Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).  

RGBP owns a very valuable patent portfolio and CEO David Koos has worked hard behind the scenes getting all the expired Patents updated a logical step for an acquiring company to take over the patents then turn around and file an FDA IND post buy out in order to immediately place those candidate drug Patents in their clinical trials pipeline. On July 13 RGBP filed an 8k listing the Company’s extensive list of issued patents and pending patents which we reported on here. 

RGBP CEO David Koos has over 30 years of investment banking and venture capital experience.  He has a deep knowledge of startup businesses, public markers and SEC reporting companies.  Dr. Koos has extensive relationships with large and small financial institutions, hedge funds and entities that Regen BioPharma expects to leverage for company growth. Dr. Koos has a Ph.D. in Sociology and a Doctor of Business Administration with an emphasis in finance.  Additionally, he has authored / co-authored numerous peer reviewed journal articles. Dr. Koos worked hard to get the filings up to date and get the Company compliant which has recently been completed with RGBP now “pink current” 

To Find out the inside Scoop on RGBP Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RGBP

On November 17 RGBP released the first press release since going “pink current” reporting it has signed a non-binding LOI to acquire Canary Oncoceutics, Inc., a new company developing in vitro precision oncology tests using cellular technology. This comes after RGBP skyrocketed to $0.175 earlier this year when its subsidiary KCL Therapeutics, Inc. entered into the initial agreement with Oncology Pharma, Inc. whereby KCL granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021. In order for this acquisition to close, Regen must raise $50 million to support the development of the diagnostic platform. 

Canary Oncoceutics, Inc. is developing a precision oncology testing platform that will complement existing cancer genomic testing. Cancer genomic testing involves analyzing a sample of a cancer tumor to see how active certain genes are and if they are abnormally modified. The activity level of these genes affects factors including how likely the cancer is to grow and spread. By identifying the genetic alterations that are unique to a patient’s individual cancer, doctors are able to identify specific drugs designed to target those mutations. However, the list of drugs generated by genomic testing may be quite extensive and different patients respond differently to the same drug. 

Canary Oncoceutics, Inc. is developing tests that take those recommendations and test them on a patient’s tumor in a laboratory setting thereby allowing doctors to refine the list of recommendations generated through genomic testing down to those drugs or drug combinations which will work best on that specific patient. 

“This revolutionary functional approach to precision oncology is enabled by technology which Canary Oncoceutics, Inc. is in the process of licensing from Cornell University”, says Dr. Harry Lander, its CEO.  “The technology creates a fully vascularized patient tumor in vitro by using endothelial cells and tumor obtained from the patient via biopsy.  No artificial scaffolds or devices are needed and this allows for the perfusion of patient blood in this patient-derived tumoroid. The system is being designed to test various drugs for tumor killing as well as the effect the drugs have on tumor stem cells.” 

RGBP CEO David Koos stated: “Companion diagnostics in precision oncology is where the future of cancer treatment is heading.  The global cancer diagnostics market was $168 billion in 2020 and is expected to reach $280 billion by 20281.” Of course, this number includes imaging, tumor biopsy, laboratory tests, endoscopy, surgery and genetic testing but clearly, there is a large opportunity for functional testing that Canary Oncoceutics, Inc. is developing.  Our strategic planning aims for us to capitalize on the latest breakthroughs in science so that Regen can be part of the future of cancer treatment and diagnostics.” 

For more on RGBP Subscribe Right Now!

RGBP is getting noticed by some heavy hitters after the Company reported earlier this week in its first press release since going “pink current” it has signed a non-binding LOI to acquire Canary Oncoceutics, Inc., a new company developing in vitro precision oncology tests using cellular technology. This comes after RGBP skyrocketed to $0.175 earlier this year when its subsidiary KCL Therapeutics, Inc. entered into the initial agreement with Oncology Pharma, Inc. whereby KCL granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021. In order for this acquisition to close, Regen must raise $50 million to support the development of the diagnostic platform. Canary Oncoceutics, Inc. is developing a precision oncology testing platform that will complement existing cancer genomic testing. Cancer genomic testing involves analyzing a sample of a cancer tumor to see how active certain genes are and if they are abnormally modified. By identifying the genetic alterations that are unique to a patient’s individual cancer, doctors are able to identify specific drugs designed to target those mutations. However, the list of drugs generated by genomic testing may be quite extensive and different patients respond differently to the same drug. Canary is developing tests that take those recommendations and test them on a patient’s tumor in a laboratory setting thereby allowing doctors to refine the list of recommendations generated through genomic testing down to those drugs or drug combinations which will work best on that specific patient. According to CEO David Koos The global cancer diagnostics market was $168 billion in 2020 and is expected to reach $280 billion by 20281.” RGBP has major liquidity and trades $1 million per day in dollar volume on a slow day, investors are looking for a break over recent highs of $0.175 reached when the Company first signed an agreement with Canary back in April. We will be updating on RGBP when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with RGBP.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in RGBP either long or short and we have not been compensated for this article

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.